Boston Scientific Total Revenue

The latest total revenue for BSX is $21B as of June 2026. That compares with $18B in the prior-year period — up 13.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Boston Scientific's historical trend and sector peers before judging valuation or financial health.

Over the past year, BSX's total revenue moved from $18B to $21B — a 13.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Boston Scientific's operating scale or balance-sheet position.

Against Healthcare companies, BSX currently prints $21B for total revenue, while the sector average sits near $110B. That is roughly 81.4% below the sector mean. Large gaps often invite a closer look at Boston Scientific's growth, margins, and balance sheet.

A total revenue figure of $21B for BSX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting BSX's total revenue ($21B), review year-over-year change from $18B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.